XS-060
Based on 1 Customer Validation
XS-060 is a potent anticancer agent and RXRα antagonist. XS-060 significantly induces RXRα-dependent mitotic arrest by inhibiting pRXRα-PLK1 interaction. XS-060 inhibits p-RXRα interaction with PLK1 but has no effect on RXRα heterodimerization with RARγ. XS-060 inhibits the in situ interaction between p-RXRα and PLK1 at the centrosome.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.67%
- CAS No.: 346721-50-4
- Formule: C20H18N2O3
- Masse moléculaire:334.37
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Transcription Factor-Targeted Library
HY-L090
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
Nuclear Receptor Compound Library
HY-L126
-
Metabolic Enzyme Compound Library
HY-L146
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Activité biologique
RXRα (Retinoid X receptor alpha)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | IC50 |
>30 μM
Compound: S19
|
Inhibition of IDO1 in IFN-gamma stimulated human HeLa cells assessed as reduction in kynurenine production using L-tryptophan as substrate incubated for 24 hrs
Inhibition of IDO1 in IFN-gamma stimulated human HeLa cells assessed as reduction in kynurenine production using L-tryptophan as substrate incubated for 24 hrs
|
[PMID: 31610376] |
| MDA-MB-231 | IC50 |
6.88 μM
Compound: XS-060
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 37058970] |
XS-060 targeting the RXRα′ s coactivator binding site can inhibit pRXRα-PLK1 interaction and exhibits good antitumor activity as an anti-mitotic agent[1].
XS-060 shows anti-proliferative activity against MDA-MB 231 cancer cells, with an IC50 of 6.880 ± 0.059 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB 231, A549, and HepG2
-
Concentration:5 μM
-
Incubation Time:
-
Result:Showed anti-proliferative activity at 5 μM against cancer cells (MDA-MB 231, A549, and HepG2), with cell viability rate (%) of 51.93 ± 4.32, 82.65 ± 2.84, and 48.65 ± 6.45, respectively.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley rats (10-14 weeks, 200-220g)[1]
-
Dosage:25 mg/kg
-
Administration:Oral absorption (p.o.) and intraperitoneal injection (i.p.), once, (Pharmacokinetic Analysis)
-
Result:The oral absorption of XS-060 is very poor, while intraperitoneal injection displayed good absorption[1].
Pharmacokinetic Parameters of XS-060 in Sprague-Dawley rats[1].
XS060 25 mg/kg (i.p.) Tmax (h) 2.67 ± 1.12 Cmax (μg/L) 1061.50 ± 399.20 AUC0-∞ (μg⋅h/L) 7040.30 ± 1593.52 T1/2 (h) 2.13 ± 0.05 CLz/F (L/(h⋅kg)) 3.67 ± 0.81 Vd, z/F (L/kg) 11.31 ± 2.71